Pulse Biosciences Announces NANOPULSE-AF Study Reaches Enrollment Midpoint

What Happened
Pulse Biosciences announced on July 29, 2026 that it has surpassed the enrollment midpoint in its NANOPULSE-AF clinical study, a prospective, multicenter, pivotal investigation of the nPulse™ Cardiac Catheter System for treating recurrent, drug‑resistant, symptomatic paroxysmal atrial fibrillation. The Study began in April 2026 and is expected to enroll patients at up to 30 sites, including locations outside the United States. The company attached a press release as Exhibit 99.1 to the 8-K.

Key Details

• Announcement date: July 29, 2026.
• Study start date: April 2026.
• Study scope: Prospective, multicenter, pivotal (IDE/private) study for the nPulse Cardiac Catheter System.
• Planned sites: Up to 30 sites, including international locations; the filing notes the enrollment midpoint has now been surpassed.

Why It Matters
Hitting the enrollment midpoint is a material clinical milestone that indicates the trial is progressing toward completion and eventual data readout. For investors, this can reduce near‑term clinical development risk and keep the company on track for subsequent regulatory steps or commercial milestones tied to the trial results. The 8-K does not disclose enrollment numbers, timelines for final data, or financial impacts.